Condition: Non-small Cell Lung Cancer · Sponsor: Daiichi Sankyo
Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.
This description comes directly from the study's public registry record.
Contact for Clinical Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Not Yet Recruiting |
| Peking University International Hospital | Beijing, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, China | Not Yet Recruiting |
| Hunan Second People's Hospital | Changsha, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Not Yet Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, China | Not Yet Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Not Yet Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, China | Not Yet Recruiting |
| First Affiliated Hospital of Shandong First Medical University | Jinan, China | Not Yet Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Jinzhou Medical University | Jinzhou, China | Not Yet Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06809764